Navigation Links
FDA Provides Clarity to Isis Regarding the Development Path for Mipomersen
Date:4/25/2008

ng Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2007, which is on file with the SEC. Copies of this and other documents are available from the Company.

Isis Pharmaceuticals is a registered trademark of Isis Pharmaceuticals, Inc. Ibis Biosciences and Ibis T5000 are trademarks of Ibis Biosciences, Inc. Regulus Therapeutics is a trademark of Regulus Therapeutics LLC.

GENZYME SAFE HARBOR STATEMENT

This press release contains forward-looking statements, including without limitation, statements concerning mipomersen's benefits for patients with high cholesterol, the development plan for mipomersen and FDA's requirements for its approval. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those forecasted. These risks and uncertainties include, among others: the timing of further discussions with FDA regarding the approval of mipomersen; the timing and content of submissions to and decisions made by the FDA relating to mipomersen; further analysis of clinical trial data; the results of other studies; the actual efficacy and safety of mipomersen; and the risks and uncertainties described in Genzyme's SEC reports filed under the Securities Exchange Act of 1934, including the factors discussed under the caption "Risk Factors" in Genzyme's 2007 Annual Report on Form 10K. Genzyme cautions investors not to place substantial reliance on the forward-looking statements contained in this press release. These statements speak only as of today's date and Genzyme undertakes no obligation to update or revise the statements.

Genzyme(R) is a registered trademark of Genzyme Corporation. All rights reserved.

CONFERENCE CALL INFORMATION

At 8:00 a.m. Eastern Time Friday, April 25, Isis will conduct a live webcast conference call to discuss the mipomersen regulatory update. Interested parties may access the webcast at
'/>"/>

SOURCE Genzyme Corp. and Isis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Study provides hope that some transplant patients could live free of antirejection drugs
2. Study provides hope that some transplant patients could live free of anti-rejection drugs
3. USAID Provides Additional Wildfire Assistance to Greece
4. LifeMasters Provides Tips for Maintaining a Healthy Blood Cholesterol Level
5. New knock-out gene model provides molecular clues to breast cancer
6. PreMD Provides Update on 510(k) Application for PREVU(x) POC
7. SIV infection of natural hosts provides new insights into HIV disease complexity
8. Microarray provides 3 genomic guides to breast cancer treatment decisions
9. Access Innovations Provides Support Services for Agis Network
10. Crdentias VP of Marketing, Christina Hogan, Provides Exclusive Interview on Marketing Strategy
11. Physical Therapist Provides Injury Analysis for Fantasy Football
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... (PRWEB) September 22, 2014 The New ... Department of Surgery at the Icahn School of Medicine ... New York Group for Plastic Surgery gives residents of ... to a team of world-renowned plastic surgeons performing innovative ... Andrew Salzberg, MD, who led NYGPS, was named the ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 WHO: ... center and customer service solutions. , WHAT: The ... focused on customer care for the connected consumer. ... continue to offer new challenges and opportunities for ... helping attendees identify best practices, network and learn ...
(Date:9/22/2014)... CA (PRWEB) September 22, 2014 ... California for a three-day conference to discuss brain-related ... brain injury from concussions and neurodegenerative disorders. ... medical director affiliated with a Silverado memory care ... of dedicated expertise in memory care, hosts the ...
(Date:9/22/2014)... ARBOR, Mich. Many parents whose kids participate in ... concussion education, but that,s not enough to ensure parents ... new University of Michigan C.S. Mott Children,s Hospital National ... half of the 912 parents of middle and high ... concussion education: , , 23% have read a ...
(Date:9/22/2014)... (Sept. 22, 2014) The success of a colonoscopy ... bowel prep often resulting in missed precancerous lesions, according ... Task force on Colorectal Cancer. Additionally, poor bowel cleansing ... procedures. Up to 20 to 25 percent of all ... , "When prescribing bowel preparation for their patients, ...
Breaking Medicine News(10 mins):Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 2Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 3Health News:LiveOps To Lead Panel Discussion At Customer Response Summit Memphis 2Health News:Nation’s Leading Brain Health Experts Gather for Annual Silverado Medical Director Conference 2Health News:Nation’s Leading Brain Health Experts Gather for Annual Silverado Medical Director Conference 3Health News:Some concussion education more useful than others, parents say 2Health News:Good bowel cleansing is key for high-quality colonoscopy 2Health News:Good bowel cleansing is key for high-quality colonoscopy 3
... Something rotten never smelled so sweet. This is ... Laboratory (CSHL) are telling one another as they discuss a new ... that hydrogen sulfide (H2S) the flammable, highly toxic gas that ... and sewers plays an important role in the regulation of ...
... lifestyle habits relate to the risk of certain cancers (e.g., ... authors estimate the proportion of cancer in the population associated ... find that smoking has, by far, the largest effect on ... the UK attributable to tobacco use. A poor diet ...
... their arms asymmetrically -- one arm swings less than ... easily detected early when drugs and other interventions may ... who used inexpensive accelerometers on the arms of Parkinson,s ... known for some time that people with Parkinson,s disease ...
... York, NY, December 13, 2011JDRF-funded researchers have begun enrolling ... study, to test whether metformina drug commonly used to treat ... cardiovascular complications in people with T1D. The REMOVAL study ... multi-center, international trial that will study 500 patients with T1D ...
... Ph.D., Associate Professor of Surgery at Thomas Jefferson University ... and Related Cancers Center , and Mon-Li Chu, ... Dermatology and Cutaneous Biology , were awarded $200,000 from ... Concept Program for their breakthrough work on a ...
... or a bed has to deal with numerous complications. ... physicians call them. Bony prominences, such as the sacrum, ... can lead to tissue necrosis. Damage can extend into ... The ulcers are entryways for germs, which can trigger ...
Cached Medicine News:Health News:Unexpected signaling role for foul-smelling hydrogen sulfide in cell response to protein misfolding 2Health News:Unexpected signaling role for foul-smelling hydrogen sulfide in cell response to protein misfolding 3Health News:Increased arm swing asymmetry is early sign of Parkinson's disease 2Health News:Increased arm swing asymmetry is early sign of Parkinson's disease 3Health News:JDRF-funded study seeks to reduce cardiovascular risk 2Health News:Thomas Jefferson University receives Science Center's QED Award for pancreatic cancer research 2Health News:Thomas Jefferson University receives Science Center's QED Award for pancreatic cancer research 3Health News:Lying and sitting more comfortably 2
(Date:9/22/2014)... Sept. 22, 2014  Neuralstem, Inc. (NYSE MKT: CUR) announced ... at Emory University, presented long-term follow up data on ... cells in the treatment of amyotrophic lateral sclerosis (ALS ... occurred at the Annual Symposium on ALS of the ... on Friday, and was not open to the public, ...
(Date:9/22/2014)... , Sept. 22, 2014  Olympus, a ... solutions for medical and surgical procedures, among other ... deal with Munich -based Brainlab ... ® Navigation. This agreement applies to the ... cross-disciplinary U.S. sales and all distribution outside the ...
(Date:9/22/2014)... , Sept. 22, 2014  Inovio Pharmaceuticals, Inc. ... has initiated a phase I clinical trial in ... the safety, tolerability, and immunogenicity of INO-3106. This ... causes most aerodigestive cancers. Aerodigestive cancers ... cords, and parts of the esophagus and windpipe. ...
Breaking Medicine Technology:Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 2Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 3Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 4Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 2Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 3Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 4Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 2Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 3Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 4
... , , DALLAS , February ... and Central Labs events present Advanced,Biomarker Strategies in Oncology Drug Development. ... from February 4-5, 2010 . This,event is FREE for executives ... This two-day program focuses exclusively on the latest developments in,oncology biomarkers. ...
... RESEARCH TRIANGLE PARK, N.C. , Jan. 29 ... the U.S. Food and Drug Administration has approved ... in patients ages 13 years and older with primary generalized ... XR is approved for partial onset seizures ...
Cached Medicine Technology:MarketsandMarkets Partners With IIR USA for Their Event 'Advanced Biomarker Strategies in Oncology Drug Development' 2MarketsandMarkets Partners With IIR USA for Their Event 'Advanced Biomarker Strategies in Oncology Drug Development' 3FDA Approves Once-A-Day Lamictal(R)XR(TM) as Add-On Epilepsy Therapy for Primary Generalized Tonic-Clonic Seizures 2FDA Approves Once-A-Day Lamictal(R)XR(TM) as Add-On Epilepsy Therapy for Primary Generalized Tonic-Clonic Seizures 3FDA Approves Once-A-Day Lamictal(R)XR(TM) as Add-On Epilepsy Therapy for Primary Generalized Tonic-Clonic Seizures 4FDA Approves Once-A-Day Lamictal(R)XR(TM) as Add-On Epilepsy Therapy for Primary Generalized Tonic-Clonic Seizures 5FDA Approves Once-A-Day Lamictal(R)XR(TM) as Add-On Epilepsy Therapy for Primary Generalized Tonic-Clonic Seizures 6FDA Approves Once-A-Day Lamictal(R)XR(TM) as Add-On Epilepsy Therapy for Primary Generalized Tonic-Clonic Seizures 7
The first book to translate key medical data into clear guidelines capturing the highest treatment standards for heart disease....
DxRxValv contains tables and figures to summarize important clinical data and current professional society recommendations. This handy manual details precise, up-to-date information for diagnosis and...
... Dx/Rx: Coronary Thrombosis ... flowcharts which facilitate transformation ... protocols from static images ... support tools. Details precise, ...
Cardiology Intensive Board Review is geared specifically to candidates taking the Cardiovascular Boards and the Cardiovascular section of the Internal Medicine Boards....
Medicine Products: